C
Claudio Moretti
Researcher at University of Turin
Publications - 276
Citations - 8798
Claudio Moretti is an academic researcher from University of Turin. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 45, co-authored 266 publications receiving 7435 citations. Previous affiliations of Claudio Moretti include Sapienza University of Rome & École Normale Supérieure.
Papers
More filters
Journal ArticleDOI
Radial Versus Femoral Randomized Investigation in ST-Segment Elevation Acute Coronary Syndrome The RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) Study
Enrico Romagnoli,Giuseppe Biondi-Zoccai,Alessandro Sciahbasi,Luigi Politi,Stefano Rigattieri,Gianluca Pendenza,Francesco Summaria,Roberto Patrizi,Ambra Borghi,Cristian Di Russo,Claudio Moretti,Pierfrancesco Agostoni,Paolo Loschiavo,Ernesto Lioy,Imad Sheiban,Giuseppe Sangiorgi +15 more
TL;DR: Radial access in patients with ST-segment elevation acute coronary syndrome is associated with significant clinical benefits, in terms of both lower morbidity and cardiac mortality, and should become the recommended approach in these patients, provided adequate operator and center expertise is present.
Journal ArticleDOI
Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis
Silvia Monticone,Fabrizio D'Ascenzo,Claudio Moretti,Tracy Ann Williams,Tracy Ann Williams,Franco Veglio,Fiorenzo Gaita,Paolo Mulatero +7 more
TL;DR: The association between primary aldosteronism and adverse cardiac and cerebrovascular events, target organ damage, diabetes, and metabolic syndrome, compared with the association of essential hypertension was assessed.
Journal ArticleDOI
Favorable Long-Term Outcome After Drug-Eluting Stent Implantation in Nonbifurcation Lesions That Involve Unprotected Left Main Coronary Artery A Multicenter Registry
Alaide Chieffo,Se-Ung Park,Marco Valgimigli,Young Ho Kim,Joost Daemen,Imad Sheiban,Alessandra Truffa,Matteo Montorfano,Flavio Airoldi,Giuseppe Sangiorgi,Mauro Carlino,Iassen Michev,Cheol Whan Lee,Myeong Ki Hong,Seong Wook Park,Claudio Moretti,Erminio Bonizzoni,Renata Rogacka,Patrick W. Serruys,Antonio Colombo +19 more
TL;DR: Percutaneous coronary intervention with sirolimus-eluting stents or paclitaxel-eluted stents implantation in nonbifurcation left main coronary artery lesions appears safe with a long-term major adverse clinical event rate of 7.4% and a restenosis rate of 0.9%.
Journal ArticleDOI
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Marco Valgimigli,Enrico Frigoli,Sergio Leonardi,Pascal Vranckx,Martina Rothenbühler,Matteo Tebaldi,Ferdinando Varbella,Paolo Calabrò,Stefano Garducci,Paolo Rubartelli,Carlo Briguori,Giuseppe Andò,Maurizio Ferrario,Ugo Limbruno,Roberto Garbo,Paolo Sganzerla,Filippo Russo,Marco Stefano Nazzaro,Alessandro Lupi,Bernardo Cortese,Arturo Ausiello,Salvatore Ierna,Giovanni Esposito,Giuseppe Ferrante,Andrea Santarelli,Gennaro Sardella,Nicoletta De Cesare,Paolo Tosi,Arnoud W J van 't Hof,Elmir Omerovic,Salvatore Brugaletta,Stephan Windecker,Dik Heg,Peter Jüni,Gianluca Campo,Lucia Uguccioni,Corrado Tamburino,Patrizia Presbitero,Dennis Zavalloni-Parenti,Fabio Ferrari,Roberto Ceravolo,Fabio Tarantino,Giampaolo Pasquetto,Gavino Casu,Stefano Mameli,Maria Letizia Stochino,Pietro Mazzarotto,Alberto Cremonesi,Francesco Saia,Giovanni Saccone,Fabio Abate,Andrea Picchi,Roberto Violini,Salvatore Colangelo,Giacomo Boccuzzi,Vincenzo Guiducci,Carlo Vigna,Antonio Zingarelli,Andrea Gagnor,Tiziana Zaro,Simone Tresoldi,Pietro Vandoni,Marco Contarini,Armando Liso,Dellavalle A,Salvatore Curello,Fabio Mangiacapra,Rosario Evola,Cataldo Palmieri,Camillo Falcone,Francesco Liistro,Manuela Creaco,Antonio Colombo,Alaide Chieffo,Andrea Perkan,Stefano De Servi,Dionigi Fischetti,Stefano Rigattieri,Alessandro Sciahbasi,Edoardo Pucci,Enrico Romagnoli,Claudio Moretti,Luciano Moretti,Raffaele De Caterina,Marcello Caputo,Marco Zimmarino,Ezio Bramucci,Emilio Di Lorenzo,Maurizio Turturo,Roberto Bonmassari,Carlo Penzo,Bruno Loi,Ciro Mauro,Anna Sonia Petronio,Gabriele Gabrielli,Antonio Micari,Flavia Belloni,Francesco Amico,Marco Comeglio,Claudio Fresco,Isala Klinieken,Nicolas M. Van Mieghem,Roberto Diletti,Evelyn Regar,Manel Sabaté,José Francisco Díaz Fernández,Vicente Mainar,José M. de la Torre Hernández +107 more
TL;DR: The prespecified final 1-year outcomes of the MATRIX programme, designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management, are described.
Journal ArticleDOI
A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease ☆
Giuseppe Biondi-Zoccai,Marzia Lotrionte,Claudio Moretti,Emanuele Meliga,Pierfrancesco Agostoni,Marco Valgimigli,Angela Migliorini,David Antoniucci,Didier Carrié,Giuseppe Sangiorgi,Alaide Chieffo,Antonio Colombo,Matthew J. Price,Paul S. Teirstein,Evald Høj Christiansen,Antonio Abbate,Luca Testa,Julian Gunn,Francesco Burzotta,Antonio Laudito,Gian Paolo Trevi,Imad Sheiban +21 more
TL;DR: Results from randomized trials are still needed to definitely establish the role of drug-eluting stent implantation instead of the reference treatment, surgery, and it is shown that disease location predicted MACE and TVR, whereas high-risk features predicted death.